Pigenum, 40 mg 28 pcs.

Pharmacotherapeutic group: Gastric gland secretion reducing agent – proton pump inhibitor

Pharmacological action

H⁺-K⁺-ATPase inhibitor. Blocks the final stage of hydrochloric acid secretion, reduces basal and stimulated (regardless of the type of irritant) secretion of hydrochloric acid in the stomach. In duodenal ulcer associated with Helicobacter pylori, this decrease in gastric secretion increases the sensitivity of the micro-organism to antibiotics. Pantoprazole has intrinsic antimicrobial activity against Helicobacter pylori.

Indications

Peptic ulcer of the stomach or duodenum in the acute phase, Zollinger-Ellison syndrome, Helicobacter pylori eradication (in combination with antibacterial therapy), reflux esophagitis.

Pharmacological effect

Pharmacotherapeutic group: Gastric gland secretion reducing agent – proton pump inhibitor

Pharmacological action

H+-K+-ATPase inhibitor. Blocks the final stage of hydrochloric acid secretion, reduces the level of basal and stimulated (regardless of the type of stimulus) secretion of hydrochloric acid in the stomach. In case of duodenal ulcer associated with Helicobacter pylori, such a decrease in gastric secretion increases the sensitivity of the microorganism to antibiotics. Pantoprazole has its own antimicrobial activity against Helicobacter pylori.

Special instructions

Before starting therapy, the possibility of a malignant neoplasm in the stomach and esophagus should be excluded, since the use of pantoprazole reduces the severity of symptoms and may delay the establishment of the correct diagnosis. The diagnosis of reflux esophagitis requires mandatory endoscopic confirmation.

When used in patients with impaired liver function, the activity of liver enzymes in the blood plasma should be regularly monitored and pantoprazole should be discontinued if it increases.

Active ingredient

Pantoprazole

Composition

1 tab. contains:

Active substances:

pantoprazole sodium sesquihydrate 45.1 mg, which corresponds to the content of pantoprazole – 40 mg.

Excipients: sodium carbonate – 10 mg, mannitol – 42.7 mg, crospovidone – 50 mg, povidone K90 – 4 mg, calcium stearate – 3.2 mg.

Shell composition: opadry yellow (hypromellose – 79.96%, povidone K25 – 1.52%, titanium dioxide – 1.4%, yellow iron oxide dye – 0.12%, propylene glycol – 17%) – 20 mg.
Composition of the enteric coating: copolymer of methacrylic acid and ethyl acrylate [1:1] (Eudragit L-30 D-55) – 14.2 mg, triethyl citrate – 1.48 mg.

Pregnancy

If it is necessary to use pantoprazole during pregnancy, it is necessary to evaluate the expected benefit to the mother and the potential risk to the fetus.

If it is necessary to use it during lactation, the issue of stopping breastfeeding should be decided.

Experimental studies have shown that pantoprazole is excreted in breast milk.

Contraindications

Dyspepsia of neurotic origin, malignant diseases of the gastrointestinal tract, hypersensitivity to pantoprazole.

Side Effects

From the digestive system: diarrhea; rarely – nausea, pain in the upper abdomen, flatulence.

From the central nervous system: headache; rarely – weakness, dizziness; in isolated cases – initial manifestations of depressive states, visual impairment.

Dermatological reactions: rarely – rash, itching.

Other: weakness, dizziness; in isolated cases – swelling, increased body temperature.

Interaction

With simultaneous use, pantoprazole may alter the absorption of drugs whose absorption depends on the pH of the gastric contents (ketoconazole).

Due to the fact that pantoprazole is metabolized in the liver by the cytochrome P450 enzyme system, the possibility of drug interactions with drugs metabolized by the same enzyme system cannot be excluded.

Manufacturer

Sanovel Pharmaco-Industrial Trading Company, Türkiye